Sign in
SABSW Stock Price, Chart, Stats & News
SAB Biotherapeutics, Inc.
Save
SAB Biotherapeutics, Inc. (SABSW) does not currently pay a dividend.
133,814
Market cap
–
Current P/E
–
Forward P/E
SABSW chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | 7.68% |
ROE | 15.17% |
D/E | 0.04x |
Interest coverage ratio | -203.41x |
SABSW valuation
P/E | – |
P/S | – |
P/B | 0.49x |
P/CF | -1.66x |
P/FCF | -0.81x |
P/OCF | -1.66x |
PEG | -0.07x |
EV multiple | 2.48x |
About
SAB Biotherapeutics, Inc. is a biopharmaceutical firm specializing in the development of immunotherapies. Their efforts are directed towards combating various health challenges, such as infectious and autoimmune diseases, as well as oncology. Among their notable therapeutic candidates are SAB-142, an anti-thymocyte globulin intended for Type 1 diabetes; SAB-176, which targets seasonal influenza; and SAB-301, developed to counter Middle East Respiratory Syndrome Coronavirus (MERS-COV).
Similar securities
Based on sector and market capitalization
Report issue